English
ASX 200 reporting season
Goodman Group profits rebound while Whitehaven Coal sees decline
Goodman Group reports a significant profit recovery, contrasting with Whitehaven Coal's profit decline, while Telix Pharmaceuticals undergoes transformative growth with increased revenue.
(AI video summary)
This video was created on 20 August for IG audiences by ausbiz.
Key financial results
Goodman Group (ASX:GMG)
Goodman Group reported a statutory profit of $1.67 billion, a significant rebound from a $99 million loss in the previous year. The group aims for earnings growth by financial year (FY) 2026 with a 13% increase in operating profit to $2.31 billion by FY 2025. Assets under management rose 9% to $85.5 billion. The company plans a 30% distribution per security and a 9% growth in operating earnings per share (EPS) in FY 2026. Net tangible assets per security increased 25% to $11.03, and gearing improved to 4.3%.
Whitehaven Coal (ASX:WHC)
Whitehaven Coal, Australia’s largest independent coal miner, saw a 57% drop in annual profit due to lower coal prices and higher costs. The underlying profit was $390 million, down from $740 million. Revenue rose 53% to $5.83 billion. A $0.06 per share dividend and a $48 million share buyback plan were announced.
Telix Pharmaceuticals (ASX:TLX)
Telix Pharmaceuticals reported a US$4.8 million loss before tax, with gross profit up to $209 million. Increased spending was noted in research, development, and marketing. Revenue jumped 63% to $390 million, marking the first half of 2025 as transformative. The company is focused on new product approvals and expanding geographically.
Important to know
This information has been prepared by IG, a trading name of IG Australia Pty Ltd. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
Ready to open an IG account?
Start your trading journey now
